Zacks: Brokerages Expect SAGE Therapeutics Inc (SAGE) Will Post Earnings of -$2.40 Per Share

Equities analysts expect that SAGE Therapeutics Inc (NASDAQ:SAGE) will report earnings of ($2.40) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for SAGE Therapeutics’ earnings. The lowest EPS estimate is ($2.68) and the highest is ($2.02). SAGE Therapeutics posted earnings per share of ($1.97) during the same quarter last year, which would indicate a negative year over year growth rate of 21.8%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 1st.

On average, analysts expect that SAGE Therapeutics will report full-year earnings of ($7.37) per share for the current financial year, with EPS estimates ranging from ($9.21) to ($5.24). For the next financial year, analysts expect that the company will report earnings of ($10.42) per share, with EPS estimates ranging from ($20.74) to ($5.06). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.84) by $1.48. The firm had revenue of $90.00 million for the quarter.

A number of equities analysts recently weighed in on the stock. Piper Jaffray Companies assumed coverage on shares of SAGE Therapeutics in a research note on Monday, August 6th. They set an “overweight” rating and a $206.00 target price for the company. BidaskClub downgraded shares of SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 27th. Cowen reissued a “buy” rating and set a $207.00 target price on shares of SAGE Therapeutics in a research note on Thursday, June 14th. Canaccord Genuity reissued a “buy” rating and set a $220.00 target price on shares of SAGE Therapeutics in a research note on Tuesday, June 12th. Finally, Morgan Stanley lifted their target price on shares of SAGE Therapeutics from $225.00 to $228.00 and gave the stock an “overweight” rating in a research note on Friday, July 13th. Two research analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. SAGE Therapeutics currently has an average rating of “Buy” and an average target price of $199.19.

NASDAQ SAGE traded down $3.38 during mid-day trading on Monday, reaching $142.63. 349,600 shares of the stock were exchanged, compared to its average volume of 499,493. SAGE Therapeutics has a one year low of $59.57 and a one year high of $195.97. The company has a market capitalization of $6.81 billion, a PE ratio of -20.54 and a beta of 2.90.

A number of large investors have recently bought and sold shares of the business. Flinton Capital Management LLC grew its holdings in shares of SAGE Therapeutics by 1,900.0% during the second quarter. Flinton Capital Management LLC now owns 680 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 646 shares during the last quarter. US Bancorp DE grew its holdings in shares of SAGE Therapeutics by 5,593.3% during the second quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 839 shares during the last quarter. Creative Planning acquired a new position in shares of SAGE Therapeutics during the second quarter valued at about $210,000. Atria Investments LLC acquired a new position in shares of SAGE Therapeutics during the second quarter valued at about $218,000. Finally, Tiverton Asset Management LLC acquired a new position in shares of SAGE Therapeutics during the second quarter valued at about $229,000.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: Market Capitalization – What it Means for Investors

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply